Nyxoah: Post-Approval Evidence and U.S. Launch Could Turn Genio into a Niche Monopoly
Nyxoah's Genio bilateral neurostimulation platform is already CE-Mark validated and is beginning its U.S. post-approval program. Recent financing ($110M equity + $15M EIB debt) gives the company runway to commercialize in the U.S. — a move that could allow Nyxoah to capture an outsized share of a multi-billion dollar obstructive sleep apnea opportu…